Beth Angel McPatriot
@AngelMcPatriot
15 September, 01:12
Ivermectin for prostate cancer
Ivermectin inhibits AR pathway in prostate cancer models.
Resistance to AR pathway inhibitors in prostate cancer is associated with AR amplification, mutations, and expression of truncated AR variants, the latter characterized by loss of AR’s ligand-binding domain and constitutively active transcription (24).
https://www.ncbi.nlm.nih.g...
Ivermectin inhibits AR pathway in prostate cancer models.
Resistance to AR pathway inhibitors in prostate cancer is associated with AR amplification, mutations, and expression of truncated AR variants, the latter characterized by loss of AR’s ligand-binding domain and constitutively active transcription (24).
https://www.ncbi.nlm.nih.g...
Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models - PMC
HSP27 is highly expressed in, and supports oncogene addiction of, many cancers. HSP27 phosphorylation is a limiting step for activation of this protein and a target for inhibition, but its highly disordered structure challenges rational structure-guided ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994194/#:~:text=Ivermectin%20inhibits%20AR%20pathway%20in,constitutively%20active%20transcription%20(24).Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
04:24 AM - Sep 15, 2022
In response Beth Angel McPatriot to her Publication
Only people mentioned by suehack in this post can reply
